Welgene Biotech Co.,Ltd. (TPEX:6661)

Welgene Biotech Statistics

Total Valuation

Welgene Biotech has a market cap or net worth of TWD 372.87 million. The enterprise value is 393.62 million.

Market Cap	372.87M
Enterprise Value	393.62M

Important Dates

The next estimated earnings date is Monday, August 10, 2026.

Earnings Date	Aug 10, 2026
Ex-Dividend Date	n/a

Share Statistics

Welgene Biotech has 23.30 million shares outstanding.

Current Share Class	23.30M
Shares Outstanding	23.30M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	10.49%
Owned by Institutions (%)	n/a
Float	6.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.98
PB Ratio	1.33
P/TBV Ratio	1.44
P/FCF Ratio	n/a
P/OCF Ratio	18.08
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.41, with an EV/FCF ratio of -8.41.

EV / Earnings	-1,017.10
EV / Sales	1.03
EV / EBITDA	15.41
EV / EBIT	n/a
EV / FCF	-8.41

Financial Position

The company has a current ratio of 1.96, with a Debt / Equity ratio of 0.78.

Current Ratio	1.96
Quick Ratio	1.59
Debt / Equity	0.78
Debt / EBITDA	8.54
Debt / FCF	-4.66
Interest Coverage	-0.14

Financial Efficiency

Return on equity (ROE) is 0.01% and return on invested capital (ROIC) is -0.20%.

Return on Equity (ROE)	0.01%
Return on Assets (ROA)	-0.06%
Return on Invested Capital (ROIC)	-0.20%
Return on Capital Employed (ROCE)	-0.12%
Weighted Average Cost of Capital (WACC)	3.99%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.68
Inventory Turnover	5.20

Taxes

Income Tax	-7,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.58% in the last 52 weeks. The beta is 0.19, so Welgene Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.19
52-Week Price Change	-25.58%
50-Day Moving Average	18.04
200-Day Moving Average	19.27
Relative Strength Index (RSI)	22.01
Average Volume (20 Days)	9,696

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Welgene Biotech had revenue of TWD 381.82 million and -387,000 in losses. Loss per share was -0.02.

Revenue	381.82M
Gross Profit	161.62M
Operating Income	-531,000
Pretax Income	16,000
Net Income	-387,000
EBITDA	15.55M
EBIT	-531,000
Loss Per Share	-0.02

Balance Sheet

The company has 202.29 million in cash and 218.06 million in debt, with a net cash position of -15.77 million or -0.68 per share.

Cash & Cash Equivalents	202.29M
Total Debt	218.06M
Net Cash	-15.77M
Net Cash Per Share	-0.68
Equity (Book Value)	279.90M
Book Value Per Share	11.80
Working Capital	147.61M

Cash Flow

In the last 12 months, operating cash flow was 20.63 million and capital expenditures -67.45 million, giving a free cash flow of -46.82 million.

Operating Cash Flow	20.63M
Capital Expenditures	-67.45M
Depreciation & Amortization	16.08M
Net Borrowing	19.29M
Free Cash Flow	-46.82M
FCF Per Share	-2.01

Margins

Gross margin is 42.33%, with operating and profit margins of -0.14% and -0.10%.

Gross Margin	42.33%
Operating Margin	-0.14%
Pretax Margin	0.00%
Profit Margin	-0.10%
EBITDA Margin	4.07%
EBIT Margin	-0.14%
FCF Margin	n/a

Dividends & Yields

Welgene Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-0.10%
FCF Yield	-12.56%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on August 17, 2018. It was a forward split with a ratio of 1.08.

Last Split Date	Aug 17, 2018
Split Type	Forward
Split Ratio	1.08

Scores

Altman Z-Score	n/a
Piotroski F-Score	4